Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

The primary focus in scaling up production should first be the adoption of lean manufacturing principles used in virtually ...

Josh Ludwig is global commercial director at ScaleReady, where he leads a team of scientists that drives new business through ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Strengthening strategic partnerships and expanding client base through North America-Asia manufacturing hubs ■  Targeting ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...